Nuvalent, Inc. (NUVL) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
Balance sheet quality for NUVL: current ratio of 15.3. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $123.96 |
| Market Cap | $9.1B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 8.30 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 16.14 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| NUVL | Nuvalent, Inc. | $9.1B | 8.30 | ||
| JAZZ | Jazz Pharmaceuticals plc | $15.5B | 15.84 | 3.17 | 21.4% |
| ARWR | Arrowhead Pharmaceuticals, Inc. | $9.3B | 19.78 | -0.3% | |
| AXSM | Axsome Therapeutics, Inc. | $10.9B | |||
| ABVX | Abivax S.A. | $7.5B | 15.11 | -73.9% | |
| CYTK | Cytokinetics, Incorporated | $9.1B | 119.0% | ||
| CRSP | CRISPR Therapeutics AG | $5.0B | 2.86 |
Price Performance
| 1 month | +0.00% |
| 3 months | +0.43% |
| Year-to-date | +23.23% |
| 1 year | +57.63% |
| 3 years | +178.69% |
52-Week Range
| 52-week High | $123.99 |
| 52-week Low | $71.13 |
| Avg Volume (90d) | 1.7M |
Related companies: ABVX · ARWR · AXSM · CRSP · CYTK · JAZZ · MRUS
Explore sector: Healthcare · Biotechnology
More sections of NUVL: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks